MedTrace Logo

NAFLD in Diabetes Type 2 in Primary Care

NCT03864510 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 317

Last updated 2025-12-12

No results posted yet for this study

Summary

The EPSONIP (Evaluating Prevalence and Severity Of NAFLD In Primary care) trial is a longitudinal cohort study of patients with T2DM recruited from primary health care centers in Östergötland, Sweden. The latest MRI techniques will be used to quantify the amount of hepatic fat, inflammation, liver fibrosis and body composition. Each patient will be investigated twice with three years apart to determine patients with progressive disease.

Conditions

  • NAFLD

Sponsors & Collaborators

  • Linkoeping University

    lead OTHER_GOV

Principal Investigators

  • Mattias Ekstedt, MD, PhD · LiU

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03864510 on ClinicalTrials.gov